CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
PARIS and BOSTON, Jan. 06, 2017 -- NEOVACS (Alternext Paris:ALNEV), leader in active immunotherapy for the treatment of autoimmune diseases, today announced that Neovacs will participate in two upcoming investor events in the United States and France.
Neovacs will be participating in the LifeSci Advisors Corporate Access Event, hosting one-on-one meetings with investors January 9-11 at the Sir Francis Drake Hotel in San Francisco, CA. This event is being held around the 35th Annual J.P Morgan Healthcare Conference.
Neovacs will present a corporate overview at the Biomed Event - 2nd edition - on January 26 at the Salon Hoche in Paris, France. This event is being sponsored by Invest Securities, and brings together leading biotechnology-focused European institutional investors and leading European biotechnology companies.
Neovacs’ management team is available to meet with investors at both events. To request a meeting, please send an email to: [email protected].
About Neovacs
Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts NEOVACS – Corporate Communications & Investor Relations Charlène Masson +33 (0)1 53 10 93 00 [email protected] LIFESCI ADVISORS- Investor Relations / Financial Communications – Chris Maggos [email protected]
